Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis

In the original short treatment regimen for rifampicin-resistant tuberculosis, bedaquiline proved an adequate core drug for fluoroquinolone resistance, ensuring early conversion and relapse-free cure. Use of linezolid did not have the same early effect. https://bit.ly/3gWuf9z

Detalles Bibliográficos
Autores principales: Decroo, Tom, Aung, Kya Jai Maug, Hossain, Mohamed Anwar, Gumusboga, Mourad, Ortuno-Gutierrez, Nimer, De Jong, Bouke Catherine, Van Deun, Armand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943272/
https://www.ncbi.nlm.nih.gov/pubmed/34561288
http://dx.doi.org/10.1183/13993003.02124-2021
_version_ 1784673481748643840
author Decroo, Tom
Aung, Kya Jai Maug
Hossain, Mohamed Anwar
Gumusboga, Mourad
Ortuno-Gutierrez, Nimer
De Jong, Bouke Catherine
Van Deun, Armand
author_facet Decroo, Tom
Aung, Kya Jai Maug
Hossain, Mohamed Anwar
Gumusboga, Mourad
Ortuno-Gutierrez, Nimer
De Jong, Bouke Catherine
Van Deun, Armand
author_sort Decroo, Tom
collection PubMed
description In the original short treatment regimen for rifampicin-resistant tuberculosis, bedaquiline proved an adequate core drug for fluoroquinolone resistance, ensuring early conversion and relapse-free cure. Use of linezolid did not have the same early effect. https://bit.ly/3gWuf9z
format Online
Article
Text
id pubmed-8943272
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-89432722022-03-28 Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis Decroo, Tom Aung, Kya Jai Maug Hossain, Mohamed Anwar Gumusboga, Mourad Ortuno-Gutierrez, Nimer De Jong, Bouke Catherine Van Deun, Armand Eur Respir J Agora In the original short treatment regimen for rifampicin-resistant tuberculosis, bedaquiline proved an adequate core drug for fluoroquinolone resistance, ensuring early conversion and relapse-free cure. Use of linezolid did not have the same early effect. https://bit.ly/3gWuf9z European Respiratory Society 2022-03-24 /pmc/articles/PMC8943272/ /pubmed/34561288 http://dx.doi.org/10.1183/13993003.02124-2021 Text en Copyright ©The authors 2022. https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org)
spellingShingle Agora
Decroo, Tom
Aung, Kya Jai Maug
Hossain, Mohamed Anwar
Gumusboga, Mourad
Ortuno-Gutierrez, Nimer
De Jong, Bouke Catherine
Van Deun, Armand
Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
title Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
title_full Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
title_fullStr Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
title_full_unstemmed Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
title_short Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
title_sort bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
topic Agora
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943272/
https://www.ncbi.nlm.nih.gov/pubmed/34561288
http://dx.doi.org/10.1183/13993003.02124-2021
work_keys_str_mv AT decrootom bedaquilinecanactascoredruginastandardisedtreatmentregimenforfluoroquinoloneresistantrifampicinresistanttuberculosis
AT aungkyajaimaug bedaquilinecanactascoredruginastandardisedtreatmentregimenforfluoroquinoloneresistantrifampicinresistanttuberculosis
AT hossainmohamedanwar bedaquilinecanactascoredruginastandardisedtreatmentregimenforfluoroquinoloneresistantrifampicinresistanttuberculosis
AT gumusbogamourad bedaquilinecanactascoredruginastandardisedtreatmentregimenforfluoroquinoloneresistantrifampicinresistanttuberculosis
AT ortunogutierreznimer bedaquilinecanactascoredruginastandardisedtreatmentregimenforfluoroquinoloneresistantrifampicinresistanttuberculosis
AT dejongboukecatherine bedaquilinecanactascoredruginastandardisedtreatmentregimenforfluoroquinoloneresistantrifampicinresistanttuberculosis
AT vandeunarmand bedaquilinecanactascoredruginastandardisedtreatmentregimenforfluoroquinoloneresistantrifampicinresistanttuberculosis

Ejemplares similares